Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OTSA101-DTPA in Synovial Sarcoma
NCT04176016Phase 1Terminated
- Sponsor
- OncoTherapy Science, Inc.
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tabituximab barzuxetan in synovial sarcoma (SS), sponsored by OncoTherapy Science, Inc. Primary endpoints: Pharmacokinetic (PK) and Biodistribution of OTSA101-DTPA-111In, Safety of OTSA101-DTPA-111In and 1 more. Started Jan 2020; status: terminated.
02
Drugs
tabituximab barzuxetan
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT04176016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176016.